Skip to main content

REVIEW article

Front. Pharmacol.
Sec. Ethnopharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1395735
This article is part of the Research Topic Natural Products in Medicine: Insights from History and Ethnopharmacology View all 10 articles

Isoliquiritigenin as a Modulator of the Nrf2 Signaling Pathway: Potential Therapeutic Implications

Provisionally accepted
Mangmang Qiu Mangmang Qiu 1Kang Ma Kang Ma 2Junfeng Zhang Junfeng Zhang 1Zhaohua Zhao Zhaohua Zhao 1*Shan Wang Shan Wang 1*Qing Wang Qing Wang 1*Hao Xu Hao Xu 1*
  • 1 Xi'an Medical University, Xi'an, Shaanxi Province, China
  • 2 Qingdao University, Qingdao, Shandong Province, China

The final, formatted version of the article will be published soon.

    Nuclear factor erythroid-2-related factor 2 (Nrf2), a transcription factor responsible for cytoprotection, plays a crucial role in regulating the expression of numerous antioxidant genes, thereby reducing reactive oxygen species (ROS) levels and safeguarding cells against oxidative stress. Extensive research has demonstrated the involvement of Nrf2 in various diseases, prompting the exploration of Nrf2 activation as a potential therapeutic approach for a variety of diseases. Consequently, there has been a surge of interest in investigating the Nrf2 signaling pathway and developing compounds that can modulate its activity. Isoliquiritigenin (ISL) (PubChem CID:638278) exhibits a diverse range of pharmacological activities, including antioxidant, anticancer, and anti-tumor properties.Notably, its robust antioxidant activity has garnered significant attention. Furthermore, ISL has been found to possess therapeutic effects on various diseases, such as diabetes, cardiovascular diseases, kidney diseases, and cancer, through the activation of the Nrf2 pathway. This review aims to evaluate the potential of ISL in modulating the Nrf2 signaling pathway and summarize the role of ISL in diverse diseases prevention and treatment through modulating the Nrf2 signaling pathway.

    Keywords: Nrf2, Isoliquiritigenin, disorders, Anti-oxidant, Natural compound Broad complex, Tramtrack and Bric-à-Brac domain bZIP: basic-region leucine zipper Caspase-3: cysteinyl aspartate specific proteinase-3

    Received: 04 Mar 2024; Accepted: 24 Sep 2024.

    Copyright: © 2024 Qiu, Ma, Zhang, Zhao, Wang, Wang and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Zhaohua Zhao, Xi'an Medical University, Xi'an, 710021, Shaanxi Province, China
    Shan Wang, Xi'an Medical University, Xi'an, 710021, Shaanxi Province, China
    Qing Wang, Xi'an Medical University, Xi'an, 710021, Shaanxi Province, China
    Hao Xu, Xi'an Medical University, Xi'an, 710021, Shaanxi Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.